A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma (original) (raw)

Abstract

The purpose of this study was to evaluate the role of interferon as initial and maintenance therapy in patients with newly diagnosed follicular lymphoma. Between 1984 and 1994, 204 patients with newly diagnosed Stage III or Stage IV follicular lymphoma were randomized to receive either, Chlorambucil (CB): 10 mg daily for 6 weeks, followed by a 2-week interval, with 3 subsequent 2-week treatment periods at the same dose, separated by 2-week intervals, or, CB given concurrently with interferon (IFN). IFN was given at a dose of 3 × 106units thrice weekly, subcutaneously, throughout the 18-week treatment period. Responding patients were subsequently randomized to receive maintenance IFN at the dose and schedule described above, or to expectant management. The overall response rate was 161/204 (78%), complete remission being achieved in 24% of patients. Neither the addition of IFN to the initial treatment, nor the use of maintenance IFN influenced response rate, remission duration or survival. This study was undertaken to determine whether IFN, given in combination with, and then subsequent to, CB would alter the clinical course of patients with follicular lymphoma. Disappointingly, this objective was not achieved, no advantage having been demonstrated for the addition of IFN. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: interferon, initial therapy, maintenance, follicular lymphoma

Full Text

The Full Text of this article is available as a PDF (100.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen J. W., Smalley R. V. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up. N Engl J Med. 1993 Dec 9;329(24):1821–1822. doi: 10.1056/NEJM199312093292419. [DOI] [PubMed] [Google Scholar]
  2. Apostolidis J., Foran J. M., Johnson P. W., Norton A., Amess J., Matthews J., Bradburn M., Lister T. A., Rohatiner A. Z. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol. 1999 Jan;17(1):216–221. doi: 10.1200/JCO.1999.17.1.216. [DOI] [PubMed] [Google Scholar]
  3. Apostolidis J., Gupta R. K., Grenzelias D., Johnson P. W., Pappa V. I., Summers K. E., Salam A., Adams K., Norton A. J., Amess J. A. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol. 2000 Feb;18(3):527–536. doi: 10.1200/JCO.2000.18.3.527. [DOI] [PubMed] [Google Scholar]
  4. Arranz R., García-Alfonso P., Sobrino P., Zamora P., Carrión R., García-Laraña J., Pérez G., López J., Lavilla E., Lozano M. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization. J Clin Oncol. 1998 Apr;16(4):1538–1546. doi: 10.1200/JCO.1998.16.4.1538. [DOI] [PubMed] [Google Scholar]
  5. Aviles A., Duque G., Talavera A., Guzman R. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival. Leuk Lymphoma. 1996 Feb;20(5-6):495–499. doi: 10.3109/10428199609052435. [DOI] [PubMed] [Google Scholar]
  6. Balkwill F. R., Moodie E. M. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res. 1984 Mar;44(3):904–908. [PubMed] [Google Scholar]
  7. Balkwill F., Taylor-Papadimitriou J. Interferon affects both G1 and S+G2 in cells stimulated from quiescence to growth. Nature. 1978 Aug 24;274(5673):798–800. doi: 10.1038/274798a0. [DOI] [PubMed] [Google Scholar]
  8. Fisher R. I., Dana B. W., LeBlanc M., Kjeldsberg C., Forman J. D., Unger J. M., Balcerzak S. P., Gaynor E. R., Roy V., Miller T. Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol. 2000 May;18(10):2010–2016. doi: 10.1200/JCO.2000.18.10.2010. [DOI] [PubMed] [Google Scholar]
  9. Foon K. A., Sherwin S. A., Abrams P. G., Longo D. L., Fer M. F., Stevenson H. C., Ochs J. J., Bottino G. C., Schoenberger C. S., Zeffren J. Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med. 1984 Nov 1;311(18):1148–1152. doi: 10.1056/NEJM198411013111803. [DOI] [PubMed] [Google Scholar]
  10. Freedman A. S., Neuberg D., Mauch P., Soiffer R. J., Anderson K. C., Fisher D. C., Schlossman R., Alyea E. P., Takvorian T., Jallow H. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15;94(10):3325–3333. [PubMed] [Google Scholar]
  11. Gallagher C. J., Gregory W. M., Jones A. E., Stansfeld A. G., Richards M. A., Dhaliwal H. S., Malpas J. S., Lister T. A. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol. 1986 Oct;4(10):1470–1480. doi: 10.1200/JCO.1986.4.10.1470. [DOI] [PubMed] [Google Scholar]
  12. Gospodarowicz M. K., Bush R. S., Brown T. C., Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984 Apr;10(4):489–497. doi: 10.1016/0360-3016(84)90028-2. [DOI] [PubMed] [Google Scholar]
  13. Gresser I., Brouty-Boyé D., Thomas M. T., Macieira-Coelho A. Interferon and cell division. I. Inhibition of the multiplication of mouse leukemia L 1210 cells in vitro by interferon preparations. Proc Natl Acad Sci U S A. 1970 Aug;66(4):1052–1058. doi: 10.1073/pnas.66.4.1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Gresser I., Maury C., Tovey M. Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer. 1978 Jan;14(1):97–99. doi: 10.1016/0014-2964(78)90143-3. [DOI] [PubMed] [Google Scholar]
  15. Gresser I., Maury C., Tovey M. Interferon and murine leukemia. VII. Therapeutic effect of interferon preparations after diagnosis of lymphoma in AKR mice. Int J Cancer. 1976 May 15;17(5):647–651. doi: 10.1002/ijc.2910170514. [DOI] [PubMed] [Google Scholar]
  16. Gutterman J. U., Blumenschein G. R., Alexanian R., Yap H. Y., Buzdar A. U., Cabanillas F., Hortobagyi G. N., Hersh E. M., Rasmussen S. L., Harmon M. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep;93(3):399–406. doi: 10.7326/0003-4819-93-3-399. [DOI] [PubMed] [Google Scholar]
  17. Hagenbeek A., Carde P., Meerwaldt J. H., Somers R., Thomas J., De Bock R., Raemaekers J. M., van Hoof A., De Wolf-Peeters C., van Glabbeke M. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol. 1998 Jan;16(1):41–47. doi: 10.1200/JCO.1998.16.1.41. [DOI] [PubMed] [Google Scholar]
  18. Horning S. J., Merigan T. C., Krown S. E., Gutterman J. U., Louie A., Gallagher J., McCravey J., Abramson J., Cabanillas F., Oettgen H. Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer. 1985 Sep 15;56(6):1305–1310. doi: 10.1002/1097-0142(19850915)56:6<1305::aid-cncr2820560614>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  19. Kaminski M. S., Zasadny K. R., Francis I. R., Fenner M. C., Ross C. W., Milik A. W., Estes J., Tuck M., Regan D., Fisher S. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996 Jul;14(7):1974–1981. doi: 10.1200/JCO.1996.14.7.1974. [DOI] [PubMed] [Google Scholar]
  20. Kantarjian H. M., McLaughlin P., Fuller L. M., Dixon D. O., Osborne B. M., Cabanillas F. F. Follicular large cell lymphoma: analysis and prognostic factors in 62 patients. J Clin Oncol. 1984 Jul;2(7):811–819. doi: 10.1200/JCO.1984.2.7.811. [DOI] [PubMed] [Google Scholar]
  21. Lawrence T. S., Urba W. J., Steinberg S. M., Sundeen J. T., Cossman J., Young R. C., Glatstein E. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys. 1988 Mar;14(3):417–424. doi: 10.1016/0360-3016(88)90254-4. [DOI] [PubMed] [Google Scholar]
  22. Leavitt R. D., Ratanatharathorn V., Ozer H., Ultmann J. E., Portlock C., Myers J. W., Kisner D., Norred S., Spiegel R. J., Bonnem E. M. Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1987 Jun;14(2 Suppl 2):18–23. [PubMed] [Google Scholar]
  23. Leonard R. C., Hayward R. L., Prescott R. J., Wang J. X. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. The Scotland and Newcastle Lymphoma Group Therapy Working Party. Ann Oncol. 1991 Oct;2(9):655–662. doi: 10.1093/oxfordjournals.annonc.a058044. [DOI] [PubMed] [Google Scholar]
  24. Lepage E., Sebban C., Gisselbrecht C., Coiffier B., Harousseau J. L., Bryon P. A., Boiron M. Treatment of low-grade non-Hodgkin's lymphomas: assessment of doxorubicin in a controlled trial. Hematol Oncol. 1990 Jan-Feb;8(1):31–39. doi: 10.1002/hon.2900080105. [DOI] [PubMed] [Google Scholar]
  25. Louie A. C., Gallagher J. G., Sikora K., Levy R., Rosenberg S. A., Merigan T. C. Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood. 1981 Oct;58(4):712–718. [PubMed] [Google Scholar]
  26. López-Guillermo A., Cabanillas F., McLaughlin P., Smith T., Hagemeister F., Rodríguez M. A., Romaguera J. E., Younes A., Sarris A. H., Preti H. A. Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol. 2000;11 (Suppl 1):137–140. [PubMed] [Google Scholar]
  27. Marquet R. L., Schellekens H., Westbroek D. L., Jeekel J. Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int J Cancer. 1983 Feb 15;31(2):223–226. doi: 10.1002/ijc.2910310215. [DOI] [PubMed] [Google Scholar]
  28. McLaughlin P., Hagemeister F. B., Romaguera J. E., Sarris A. H., Pate O., Younes A., Swan F., Keating M., Cabanillas F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996 Apr;14(4):1262–1268. doi: 10.1200/JCO.1996.14.4.1262. [DOI] [PubMed] [Google Scholar]
  29. O'Connell M. J., Colgan J. P., Oken M. M., Ritts R. E., Jr, Kay N. E., Itri L. M. Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group pilot study. J Clin Oncol. 1986 Feb;4(2):128–136. doi: 10.1200/JCO.1986.4.2.128. [DOI] [PubMed] [Google Scholar]
  30. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Nelp W. B., Glenn S., Fisher D. R., Porter B., Matthews D. C., Gooley T. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995 Aug 5;346(8971):336–340. doi: 10.1016/s0140-6736(95)92225-3. [DOI] [PubMed] [Google Scholar]
  31. Quesada J. R., Hawkins M., Horning S., Alexanian R., Borden E., Merigan T., Adams F., Gutterman J. U. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med. 1984 Sep;77(3):427–432. doi: 10.1016/0002-9343(84)90097-4. [DOI] [PubMed] [Google Scholar]
  32. Rohatiner A. Z., Johnson P. W., Price C. G., Arnott S. J., Amess J. A., Norton A. J., Dorey E., Adams K., Whelan J. S., Matthews J. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol. 1994 Jun;12(6):1177–1184. doi: 10.1200/JCO.1994.12.6.1177. [DOI] [PubMed] [Google Scholar]
  33. Rohatiner A. Z., Richards M. A., Barnett M. J., Stansfeld A. G., Lister T. A. Chlorambucil and interferon for low grade non-Hodgkin's lymphoma. Br J Cancer. 1987 Feb;55(2):225–226. doi: 10.1038/bjc.1987.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Romaguera J. E., McLaughlin P., North L., Dixon D., Silvermintz K. B., Garnsey L. A., Velasquez W. S., Hagemeister F. B., Cabanillas F. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol. 1991 May;9(5):762–769. doi: 10.1200/JCO.1991.9.5.762. [DOI] [PubMed] [Google Scholar]
  35. Rudders R. A., Kaddis M., DeLellis R. A., Casey H., Jr Nodular non-Hodgkin's lymphoma (NHL): factors influencing prognosis and indications for aggressive treatment. Cancer. 1979 May;43(5):1643–1651. doi: 10.1002/1097-0142(197905)43:5<1643::aid-cncr2820430513>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  36. Singh G., Renton K. W. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation. Mol Pharmacol. 1981 Nov;20(3):681–684. [PubMed] [Google Scholar]
  37. Smalley R. V., Andersen J. W., Hawkins M. J., Bhide V., O'Connell M. J., Oken M. M., Borden E. C. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med. 1992 Nov 5;327(19):1336–1341. doi: 10.1056/NEJM199211053271902. [DOI] [PubMed] [Google Scholar]
  38. Solal-Celigny P., Lepage E., Brousse N., Reyes F., Haioun C., Leporrier M., Peuchmaur M., Bosly A., Parlier Y., Brice P. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993 Nov 25;329(22):1608–1614. doi: 10.1056/NEJM199311253292203. [DOI] [PubMed] [Google Scholar]
  39. Soubeyran P., Eghbali H., Bonichon F., Trojani M., Richaud P., Hoerni B. Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients. Eur J Cancer. 1991;27(12):1606–1613. doi: 10.1016/0277-5379(91)90425-d. [DOI] [PubMed] [Google Scholar]
  40. Spinolo J. A., Cabanillas F., Dixon D. O., Khorana S. M., McLaughlin P., Velasquez W. S., Hagemeister F. B., Redman J. R., Swan F., Jr Therapy of relapsed or refractory low-grade follicular lymphomas: factors associated with complete remission, survival and time to treatment failure. Ann Oncol. 1992 Mar;3(3):227–232. doi: 10.1093/oxfordjournals.annonc.a058157. [DOI] [PubMed] [Google Scholar]
  41. Steward W. P., Crowther D., McWilliam L. J., Jones J. M., Deakin D. P., Todd I. D., Blackledge G., Wagstaff J., Scarffe J. H., Harris M. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer. 1988 Feb 1;61(3):441–447. doi: 10.1002/1097-0142(19880201)61:3<441::aid-cncr2820610306>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  42. Stolfi R. L., Martin D. S., Sawyer R. C., Spiegelman S. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid. Cancer Res. 1983 Feb;43(2):561–566. [PubMed] [Google Scholar]
  43. Strander H., Adamson U., Aparisi T., Broström L. A., Cantell K., Einhorn S., Hall K., Ingimarsson S., Nilsonne U., Söderberg G. Adjuvant interferon treatment of human osteosarcoma. Recent Results Cancer Res. 1978;68:40–44. doi: 10.1007/978-3-642-81332-0_7. [DOI] [PubMed] [Google Scholar]
  44. Vose J. M., Wahl R. L., Saleh M., Rohatiner A. Z., Knox S. J., Radford J. A., Zelenetz A. D., Tidmarsh G. F., Stagg R. J., Kaminski M. S. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000 Mar;18(6):1316–1323. doi: 10.1200/JCO.2000.18.6.1316. [DOI] [PubMed] [Google Scholar]
  45. Wagstaff J., Loynds P., Crowther D. A phase II study of human rDNA alpha-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chemother Pharmacol. 1986;18(1):54–58. doi: 10.1007/BF00253065. [DOI] [PubMed] [Google Scholar]